Japan's bio-AI scene compressed into one afternoon, on the argument that the moat is not the model: it is the ability to generate high-quality biological data in the first place, which is exactly where Japanese life science and precision manufacturing are strong. Craif's CEO opens, then sessions with IBM Japan's healthcare lead, Illumina Japan, and the founders of bitBiome, digzyme and Taxa Technologies on getting from research to deployed product. Startups, pharma, clinicians, investors and regulators in the room, drinks after, in-person only with a hard capacity cap.
Conference Thursday 17 September 2026 · 13:00 · Bio-AI Council
